Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 24, 2026Clinical Infectious Diseases

Fosmanogepix treatment for coccidioidomycosis under an expanded access program

View Full Paper
Ask AI
Bookmark
Share

Authors

SCStuart H. CohenPAPaul AllynFCFelicia C. Chow

Discussion

Loading...

Member takes

Overview

Expanded access program demonstrates antifungal efficacy in coccidioidomycosis, suggesting a potential treatment option.

Key Points

  • The research aims to evaluate the efficacy and safety of fosmanogepix in treating coccidioidomycosis.
  • Used an expanded access program to treat patients with coccidioidomycosis.
  • Monitored treatment outcomes and adverse effects over a median duration of 208 days.
  • Fosmanogepix was successful in treating 8 of 11 patients.
  • 75% efficacy noted in patients with meningitis.
  • 66% efficacy observed in patients with non-meningeal dissemination.

Cite This Study

Cohen et al. (2026) studied this question.

synapsesocial.com/papers/69eb08ef553a5433e34b3a54https://doi.org/10.1093/cid/ciag271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Expanded Access Fosmanogepix in Two Pediatric Patients With Rhino‐Orbital‐Cerebral Mucormycosis2026
  2. 2New Perspectives on Antimicrobial Agents: Fosmanogepix2026
  3. 3Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial2023 · 85 citations
  4. 4Manogepix demonstrates potent <i>in vitro</i> activity against <i>Aspergillus, Coccidioides</i> , <i>Scopulariopsis/Microascus, Rasamsonia</i> , and <i>Purpureocillium</i> species, including strains with <i>in vitro</i> resistance to other antifungals2026
  5. 5Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials2024 · 22 citations